The future of growth hormone antagonists

Current Opinion in Pharmacology

Volumn 2, Issue 6, 2002, Pages 730-733

  van der Lely, Aart J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; IRINOTECAN; OCTREOTIDE; PEGVISOMANT; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; DRUG DERIVATIVE; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE;

ACROMEGALY; BREAST CANCER; CLINICAL TRIAL; COLON CANCER; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPOPHYSIS ADENOMA; KIDNEY HYPERTROPHY; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; REVIEW; TRANSGENIC MOUSE; TUMOR GROWTH; DRUG ANTAGONISM; NEOPLASM;

ACROMEGALY; DIABETES MELLITUS; HUMAN GROWTH HORMONE; HUMANS; NEOPLASMS; RECEPTORS, SOMATOTROPIN;

EID: 0036905424     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(02)00226-6     Document Type: Review

References (46)

1. de Vos AM, Ultsch M, Kossiakoff AA: Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 1992, 255:306-312.
2. Abdel-Meguid SS, Shieh HS, Smith WW, Dayringer HE, Violand BN, Bentle LA: Three-dimensional structure of a genetically engineered variant of porcine growth hormone. Proc Natl Acad Sci USA 1987, 84:6434-6437.
3. Theill LE, Karin M: Transcriptional control of GH expression and anterior pituitary development. Endocr Rev 1993, 14:670-689.
4. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC: Growth hormone and bone. Endocr Rev 1998, 19:55-79.
5. Lesniak MA, Roth J, Gorden P, Gavin JR III: Human growth hormone radioreceptor assay using cultured human lymphocytes. Nat New Biol 1973, 241:20-22.
6. Carter-Su C, Rui L, Herrington J: Role of the tyrosine kinase JAK2 in signal transduction by growth hormone. Pediatr Nephrol 2000, 14:550-557.
7. Chen WY, Wight DC, Wagner TE, Kopchick JJ: Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice. Proc Natl Acad Sci USA 1990, 87:5061-5065.
8. Chen WY, White ME, Wagner TE, Kopchick JJ: Functional antagonism between endogenous mouse growth hormone (GH) and a GH analog results in dwarf transgenic mice. Endocrinology 1991, 129:1402-1408.
9. Chen WY, Wight DC, Mehta BV, Wagner TE, Kopchick JJ: Glycine 119 of bovine growth hormone is critical for growth-promoting activity. Mol Endocrinol 1991, 5:1845-1852.
10. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA: Rational design of potent antagonists to the human growth hormone receptor. Science 1992, 256:1677-1680.
11. Chen WY, Chen N, Yun J, Wagner TE, Kopchick JJ: In vitro and in vivo studies of the antagonistic effects of human growth hormone analogs. J Biol Chem 1994, 269:20806.
12. Okada S, Chen WY, Wiehl P, Kelder B, Goodman HM, Guller S, Sonenberg M, Kopchick JJ: A growth hormone (GH) analog can antagonize the ability of native GH to promote differentiation of 3T3-F442A preadipocytes and stimulate insulin-like and lipolytic activities in primary rat adipocytes. Endocrinology 1992, 130:2284-2290.
13. Veldhuis JD, Bidlingmaier M, Wu Z, Strasburger CJ: A selective recombinant human (rh) GH-receptor antagonist fails to impede metabolic removal of endogenous or exogenous GH in healthy adults: evidence that the GH receptor does not participate primarily in the in vivo GH elimination process. 11th International Congress of Endocrinology 2000, Sydney, Australia 2000,P405.
14. Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS, Zib K, Scarlett JC, Bennett WF: Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036- PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab 1999, 84:2098-2103.
15. Rodvold KA, van der Lely AJ: Pharmacokinetics and pharmacodynamics of B2036PEG, a novel growth hormone receptor antagonist, in acromegalic subjects. The Endocrine Society 81st Annual Meeting. 12-15 June, San Diego, California 1999, Abstract P1-049.
16. Melmed S: Acromegaly. N Engl J Med 1990, 322:966-977.
17. Orme SM, McNally RJ, Cartwright RA, Belchetz PE: Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998, 83:2730-2734.
18. Melmed S: Acromegaly and cancer: not a problem? J Clin Endocrinol Metab 2001, 86:2929-2934.
19. Herman-Bonert VS, Zib K, Scarlett JA, Melmed S: Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab 2000, 85:2958-2961.
20. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, vander Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML: Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000, 342:1171-1177.
21. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML et al.: Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001, 358:1754-1759.
22. Utiger RD: Treatment of acromegaly. N Engl J Med 2000, 342:1210-1211.
23. Ho KK: Place of pegvisomant in acromegaly. Lancet 2001, 358:1743-1744.
24. van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA, Lamberts SW: Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 2001, 86:478-481.
25. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998, 279:563-566.
26. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351:1393-1396.
27. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999, 91:620-625.
28. Pollak M, Blouin MJ, Zhang JC, Kopchick JJ: Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br J Cancer 2001, 85:428-430.
29. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000, 21:215-244.
30. O'Dell SD, Day IN: Insulin-like growth factor II (IGF-II). Int J Biochem Cell Biol 1998, 30:767-771.
31. Osborne CK, Clemmons DR, Arteaga CL: Regulation of breast cancer growth by insulin-like growth factors. J Steroid Biochem Mol Biol 1990, 37:805-809.
32. Duan H, Dagnaes-Hansen F, Rasmussen L, Friend KE, Orskov H, Bennet WF, Flyvbjerg A: GH receptor antagonist treatment inhibits growth of human colorectal carcinoma, COLO205 in nude mice. Program of the 5th International Symposium on Insulin-Like Growth Factors, Brighton, UK, (Abstract P13) 1999.
33. Friend KE: Targeting the growth hormone axis as a therapeutic strategy in oncology. Growth Horm IGF Res 2000, 10 Suppl A:S45-S46.
34. Friend KE, Flyvbjerg A, Bennet WF, McCutcheon IE: The growth hormone receptor antagonist pegvisomant exhibits antitumor activity in multiple preclinical tumor models. Proceedings of the 11th NCI-EORTC-AACR Symposium, Amsterdam, NL, (Abstract 420) 2000.
35. Friend KE, Radinsky R, McCutcheon IE: Growth hormone receptor expression and function in meningiomas: effect of a specific receptor antagonist. J Neurosurg 1999, 91:93-99.
36. McCutcheon IE, Flyvbjerg A, Hill H, Li J, Bennett WF, Scarlett JA, Friend KE: Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 2001, 94:487-492.
37. Yde H: Abnormal growth hormone response to ingestion of glucose in juvenile diabetics. Acta Med Scand 1969, 186:499-504.
38. Hansen AP, Johansen K: Diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone in normals and juvenile diabetics. Diabetologia 1970, 6:27-33.
39. Lundbaek K, Jensen VA, Olsen TS, Orskov H, Christensen NJ, Johansen K, Hansen AP, Osterby R: Growth hormone and diabetic angiopathy. Lancet 1970, 2:472.
40. Chen NY, Chen WY, Bellush L, Yang CW, Striker LJ, Striker GE, Kopchick JJ: Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. Endocrinology 1995, 136:660-667.
41. Chen NY, Chen WY, Kopchick JJ: A growth hormone antagonist protects mice against streptozotocin induced glomerulosclerosis even in the presence of elevated levels of glucose and glycated hemoglobin. Endocrinology 1996, 137:5163-5165.
42. Bellush LL, Doublier S, Holland AN, Striker LJ, Striker GE, Kopchick JJ: Protection against diabetes-induced nephropathy in growth hormone receptor/binding protein gene-disrupted mice. Endocrinology 2000, 141:163-168.
43. Flyvbjerg A, Bennett WF, Rasch R, Kopchick JJ, Scarlett JA: Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. Diabetes 1999, 48:377-382.
44. Segev Y, Landau D, Rasch R, Flyvbjerg A, Phillip M: Growth hormone receptor antagonism prevents early renal changes in nonobese diabetic mice. J Am Soc Nephrol 1999, 10:2374-2381.
45. Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith RG, Schaeffer JM: Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997, 276:1706-1709.
46. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group: The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 2001, 108:2266-2272.